STS and breast cancer: Previous research by our group indicated that SGLXD, the original form of mSGLXD, simultaneously downregulated aromatase and steroid sulfatase at transcription and protein levels in ER-positive breast cancer cell lines MCF-7 and T47D (44), which may underlie the anti-tumor mechanism of SGLXD.